
ABOUT PRECISION ADVANCE
Since 2013, Precision’s interdisciplinary teams have been advancing clinical, manufacturing and commercialization solutions to help innovators transform patient lives. We know that delivering a cell or gene therapy to market requires a nuanced, comprehensive and integrated approach, scientific and manufacturing expertise, and the right partner. That’s precisely why we’ve launched Precision ADVANCE, a collection of interconnected services and complementary teams uniquely focused on the complexities of clinical, regulatory, manufacturing, and commercial needs to successfully bring cell or gene therapies to market. Visit https://www.precisionmedicinegrp.com/advance/ to learn more.
WEBINARS
-
This panel features insights from industry leaders on their organization’s pipeline, the advanced therapy investment landscape, and the regulatory, manufacturing, and commercial needs to successfully bring an advanced therapy to market.
-
Learn how specializing in planning and implementing complex biomanufacturing strategies has led to the construction of more than a dozen manufacturing facilities.
-
This panel discussion features insights from industry leaders on the key considerations to make when preparing for the launch of an advanced therapy, including pricing decisions and the evidence used to support payer and HTA engagement.
-
Listen to a panel of gene therapy experts with unique perspectives and real-world experiences share successful approaches in gene therapy development, CDx development and commercialization.
-
In this webinar co-sponsored by Precision ADVANCE and Project Farma, a panel of industry experts discuss the challenges faced when building a cutting-edge cell therapy manufacturing facility.
-
Considerations for the Clinical Development of Cell & Gene Therapies is a 2-part panel discussion with our Precision experts and C-Suite leaders from advanced therapy companies on the front lines of development. Part 1 discusses Cell Therapy development, and Part 2 discusses Gene Therapy development.
-
In this Precision ADVANCE panel, industry experts share perspectives on the current state of the cell and gene therapy industry and provide key insights in shortening time-to-market for advanced therapies.
-
In this webinar, Carolyn Morgan of PRECISIONeffect moderates an expert panel exploring the challenges of commercializing a cell or gene therapy from industry trailblazers that share lessons learned from prior launches and discuss how cell and gene therapies are reshaping commercializing strategies. Some of the topics explored will be tensions between cost-effectiveness and affordability, evidence generation strategies and development, and communication to payers and health technology appraisal organizations.
VIDEOS
-
In this video, Precision experts Megan Liles and Deborah Phippard, PhD highlight the advantages that Precision ADVANCE brings to the lab.
-
Need help unravelling the complexity of CGTx development? Four experts explain Precision ADVANCE’s unique approach. Spend 50 seconds with Anshul Mangal, Deb Phippard, Megan Liles, and Philip Cyr.
-
Watch the available video to plan for success in the development of Diagnostic Assays for gene therapies.
-
Watch the available video to learn more about the team that led the industrialization of the most notable FDA-approved advanced therapies—and then created the world’s largest cell and gene therapy manufacturing footprint.
PODCASTS
-
Rare disease trials are complex under the best of circumstances—and the coronavirus pandemic has only complicated things. In this podcast, Precision’s Thijs Opdeweegh, Director, Clinical Business Solutions, and Kristi Clark, Senior Vice President, Project Management and Clinical Operations, explore the impact of decentralized operations on rare disease patients, and which new approaches are likely to become the “new normal” after COVID.
CONTACT INFORMATION
Precision ADVANCE
2 Bethesda Metro Center, Suite 850
Bethesda, MD 20814
UNITED STATES
Contact: Asha Strazzero-Wild
BROCHURES
FEATURED ARTICLES
- Part 1: Clinical Development With Cell And Gene Therapies
- Continuing The Conversation: The Future Of Reimbursement For Cell And Gene Therapies
- Gene Therapies In Hemophilia
- Gene Therapy For Rare Disorders Panel Summary
- Payers Create CAR-T Approval Systems As Adoption Increases
- Developing Advanced Therapies: Considerations For Internal Versus External Manufacturing
- What to Consider When Conducting A “Make vs. Buy” Analysis For A Cell & Gene Therapy Facility
- COVID-19 Pandemic Has Exposed The Risks Of Reliance On Foreign Markets For Critical Drug Components
- CAR T-Cell Therapy In Hematological Malignancies: Staying Ahead Of A Rapidly Evolving Landscape
- Advantages Of Using POD Cleanroom Technology
- Perspectives On Gene Therapy: Defining And Demonstrating Value To Payers
- Optimizing Successful Development Of Viral Vector Gene Therapies, Gene Therapy Trials, And Companion Diagnostics
- Ensuring Provider Education And Readiness For Using A Novel CAR T
- The Value Of Gene Therapy In Spinal Muscular Atrophy
- Mining Stakeholder Insights On Access To Gene Therapies For Hemophilia
- Process And Communication: Navigating Logistical Complexity In Matched Cellular Therapy Trials
- Navigating The CAR T-Cell Therapy Landscape To Develop Market Access And Distribution Strategies
- Delivering On The Promise Of Cell Therapy: Challenges And Trends
- Gene Therapies: Building Facilities, Commercializing Product And Industrializing The Footprint
- How To Calculate Viral Vector Yields: A Critical Component Of The “Make vs Buy” Analysis